Does Presbyterian Health Plan Cover Weight Loss Treatment in New Mexico? A 2026 Guide

Last updated: July 12, 2026

Presbyterian Health Plan (PHP) is New Mexico’s dominant regional insurer, serving hundreds of thousands of commercial, exchange, and Medicaid members through an integrated system that combines insurance, a provider network, and Presbyterian Healthcare Services hospitals. If you are a PHP commercial or exchange member in New Mexico and researching weight loss medication coverage, this guide breaks down exactly what PHP’s closed formulary covers in 2026 — including a key difference from other major national insurers that patients often find surprising.

Considering weight loss treatment in New Mexico? Klarity Health connects New Mexico residents with 2,000+ licensed providers who may prescribe FDA-approved weight loss medications. See if you may qualify →

PHP Commercial Formulary for Weight Loss Medications (2026)

Presbyterian Health Plan manages its own formulary through an internal Pharmacy and Therapeutics (P&T) Committee — it does not use OptumRx, CVS/Caremark, or Express Scripts as its PBM for commercial and exchange plans. This means PHP’s coverage decisions can differ substantially from what you may read about national pharmacy benefit managers. Mail order fills of up to a 90-day supply are available through Costco Mail Order Pharmacy for Tier 1, 2, and 3 drugs.

The table below summarizes how PHP’s commercial and exchange formulary typically treats weight loss medications in 2026.

GLP-1 Medications for Weight Loss (Wegovy, Zepbound, Saxenda)

What this means for PHP commercial members: PHP’s 2026 clinical criteria document (MPC122327, effective 07/01/2026) explicitly restricts Wegovy to Federal Employee (FEHB) plans. Standard commercial and exchange plan members may not have access to GLP-1 medications for the obesity/weight management indication through PHP’s closed formulary. This is a meaningful difference compared to UHC/OptumRx and Cigna/Express Scripts, which cover Wegovy and Zepbound commercially with prior authorization.

Ozempic and Mounjaro: The T2D Distinction

A common source of patient confusion is the difference between GLP-1 medications approved for Type 2 diabetes versus those approved for obesity management. PHP’s formulary does include a “GLP-1 Agonists (COMM/EXCH)” section for diabetes-indicated GLP-1 medications such as Ozempic (semaglutide 1 mg) and Mounjaro (tirzepatide for T2D). However, these are covered for the Type 2 diabetes indication only — not as weight loss agents. If a PHP commercial member does not have a documented T2D diagnosis, these medications may not be covered under PHP’s formulary at all.

Non-GLP-1 Weight Loss Medications

PHP’s formulary does include coverage for non-GLP-1 weight loss medications under its “Weight Loss (COMM, EXC)” section. These options typically require prior authorization and documented clinical criteria.

Note: PHP’s P&T Committee may update coverage tiers and criteria at any time. Verify your specific plan’s coverage by calling member services or checking your Evidence of Coverage document before beginning treatment.

Federal Employee Plans (FEHB) Exception

New Mexico federal employees enrolled in PHP through the Federal Employees Health Benefits (FEHB) program have different coverage than standard commercial members. Federal regulations require all FEHB plans to cover at least one GLP-1 medication for weight loss. PHP’s FEHB plans may cover Wegovy under this federal mandate. If you are a federal employee or federal retiree in New Mexico, verify your specific FEHB plan’s benefits — your coverage for weight loss medications may be more comprehensive than what is described for PHP’s standard commercial plans above.

Prior Authorization Requirements for Weight Loss Medications

For non-GLP-1 weight loss medications that require prior authorization on PHP commercial plans, criteria typically include:

• Documented diagnosis of obesity (BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or sleep apnea)
• Documentation of prior attempts at lifestyle modification (diet changes, increased physical activity, behavioral counseling) over a sustained period
• No contraindications to the specific medication requested
• Prescriber documentation of treatment plan and monitoring schedule
• For Qsymia: REMS program enrollment requirements (due to teratogenicity risk in women of childbearing age)

PA timelines under New Mexico law and PHP’s own policies typically allow:

• Standard PA: Decision within 72 hours of receiving complete documentation
• Urgent/expedited PA: Decision within 24 hours when delay would seriously jeopardize health

If your PA request is denied, you have the right to file an internal appeal followed by an external independent review. PHP must provide a written denial with specific reasons, and you may request a copy of the clinical criteria used in the determination.

EPCS (Electronic Prescribing for Controlled Substances) — Not Applicable to Weight Loss Medications

Patients and providers occasionally ask whether New Mexico’s Electronic Prescribing for Controlled Substances (EPCS) requirements affect weight loss medication prescriptions. Under New Mexico Administrative Code § 16.19.26 (implementing the controlled substance prescribing rules), and consistent with the federal EPCS standard under § 456.44, EPCS requirements apply to Schedule II controlled substances only.

None of the standard weight loss medications prescribed for obesity management are Schedule II:

• Wegovy, Zepbound, Saxenda, Contrave, orlistat: Non-controlled substances — EPCS entirely inapplicable
• Phentermine and Qsymia: Schedule IV (not Schedule II) — EPCS under § 456.44 does not apply to Schedule IV substances

This means that if a PHP FEHB member or any NM patient is prescribed a weight loss medication through a telehealth provider, there are no EPCS prescribing barriers. The prescription can be transmitted electronically through standard pharmacy workflows without the additional EPCS authentication requirements that apply to Schedule II stimulants or opioids.

New Mexico Parity Law and Weight Loss Coverage

New Mexico’s mental health parity statute, NMSA 1978 § 59A-23E-19 et seq., requires that insurers apply no more restrictive limitations on mental health and substance use disorder benefits than on comparable medical and surgical benefits. This law is an important consumer protection for PHP members seeking ADHD, anxiety, or depression treatment through telehealth.

However, weight loss treatment is not a mental health condition under the parity framework. The NM parity statute does not require PHP to cover obesity medications on the same terms as other medical treatments. For weight loss coverage disputes, the applicable frameworks are:

• ACA Essential Health Benefits (EHB): ACA individual and small group marketplace plans must cover EHBs, but weight loss prescription medications are not uniformly required as EHBs in New Mexico’s benchmark plan. This limits appeal options for coverage denials.
• Employer plan terms: Large employer (ERISA) self-funded plans are not subject to New Mexico state insurance law at all — including parity and EHB requirements — and are governed solely by federal ERISA and MHPAEA rules.
• FEHB: Federal employee plans are governed by federal OPM regulations, which now mandate GLP-1 coverage for weight loss.

Medicare GLP-1 Bridge: Not Applicable to PHP Commercial Plans

Effective July 1, 2026, eligible Medicare Advantage (MAPD) members may access Wegovy, Zepbound, or Foundayo at $50/month through a CMS Medicare GLP-1 Bridge program. This program is specifically for Medicare Advantage plan members and is processed outside Part D formularies through CMS. It does not apply to PHP commercial or exchange plan members. PHP’s Medicare Advantage plans are separate from its commercial products and have different formularies.

Getting Weight Loss Treatment Through Telehealth with PHP

If you have PHP commercial coverage and are considering weight loss treatment, the practical options available to you in 2026 include:

1. Non-GLP-1 medications: Orlistat, Contrave, phentermine, or Qsymia may be covered under PHP’s “Weight Loss (COMM, EXC)” formulary section with applicable PA requirements.
2. FEHB members: If you are a federal employee or retiree on a PHP FEHB plan, you may have access to GLP-1 medications for weight loss — verify your specific plan benefits.
3. Out-of-pocket GLP-1 access: Some patients with PHP commercial coverage choose to pay out-of-pocket for GLP-1 medications (using manufacturer savings programs where available) if the medications are not covered by their plan.

Klarity Health works with 2,000+ licensed New Mexico providers who can evaluate your clinical situation, discuss formulary options with you, and help navigate prior authorization if applicable.

Ready to explore weight loss treatment in New Mexico? See if you may qualify with Klarity Health →

PHP Contact Information

• PHP Member Services: 505-923-5678 or 1-800-356-2219 (Mon–Fri 7:00 a.m. – 6:00 p.m.)
• myPRES Assistance: 505-923-5590 or 1-866-861-7444
• Interpreter Services: 1-855-592-7737 (TTY 711)
• Costco Mail Order Pharmacy (90-day fills): Contact PHP member services for enrollment instructions
• NM Office of Superintendent of Insurance (OSI) — consumer complaints: 1-855-427-5674
• U.S. Department of Labor (ERISA/self-funded plan complaints): 1-866-444-3272

Frequently Asked Questions

Does Presbyterian Health Plan cover Wegovy or Zepbound for weight loss?

For standard PHP commercial and exchange plan members, Wegovy and Zepbound are generally not covered for the obesity/weight management indication in 2026. PHP’s clinical criteria document (effective 07/01/2026) lists Wegovy as available on Federal Employee (FEHB) plans only. If you are a New Mexico federal employee or retiree enrolled in a PHP FEHB plan, you may have GLP-1 weight loss coverage — verify your specific plan’s benefits by calling PHP member services at 1-800-356-2219.

What weight loss medications does PHP typically cover?

PHP’s standard commercial and exchange formulary typically covers non-GLP-1 weight loss medications under its “Weight Loss (COMM, EXC)” criteria: generic orlistat (Tier 1–2, generally no PA), Contrave (Tier 2–3, PA may be required), phentermine (Tier 1–2, Schedule IV, quantity limits), and Qsymia (Tier 2–3, Schedule IV, PA and REMS required). Coverage varies by specific plan and is subject to P&T Committee updates. Always verify with PHP before starting treatment.

Does the Medicare GLP-1 Bridge apply to PHP commercial members?

No. The Medicare GLP-1 Bridge (effective July 1, 2026, providing Wegovy/Zepbound/Foundayo at $50/month via CMS) applies only to Medicare Advantage (MAPD) plan members. PHP commercial and exchange plan members are not eligible for this program. It is a Medicare-specific benefit processed outside Part D formularies.

Does EPCS apply to weight loss prescriptions in New Mexico?

No. Electronic Prescribing for Controlled Substances (EPCS) under § 456.44 applies only to Schedule II controlled substances. All standard weight loss medications are either non-controlled (Wegovy, Zepbound, Contrave, orlistat) or Schedule IV (phentermine, Qsymia). Schedule IV is not Schedule II. There are no EPCS barriers to receiving weight loss prescriptions through telehealth in New Mexico.

Can I appeal if PHP denies my weight loss medication PA request?

Yes. If PHP denies your prior authorization request for a weight loss medication, you have the right to a written explanation with specific clinical reasons, an internal appeal reviewed by a different clinical reviewer, and an external independent review if the internal appeal is denied. Under New Mexico law, PA decisions must be made within 72 hours (standard) or 24 hours (urgent). You may also file a complaint with the NM OSI at 1-855-427-5674 if you believe the denial was improper for a regulated commercial plan. ERISA self-funded plan appeals go to the U.S. Department of Labor at 1-866-444-3272.

Disclaimer: Coverage information in this guide is based on publicly available PHP formulary documentation and clinical criteria effective as of the date of this publication. Individual plan coverage may differ based on your specific PHP plan type, employer group, or enrollment category. Coverage for weight loss medications is particularly variable and subject to P&T Committee changes. Always verify your specific plan’s benefits by calling PHP member services or reviewing your Evidence of Coverage before beginning any treatment. This guide is for informational purposes only and does not constitute medical or legal advice. Klarity Health providers are not PHP employees and Klarity Health cannot guarantee network participation status with any insurer.

Questions about weight loss treatment options? Klarity Health’s licensed New Mexico providers can help you understand your options and navigate coverage. See if you may qualify →